Erasca

ERAS · Nasdaq · United States

Share price · ERAS

$13.76-4.34 (-23.98%) 3M

close as of 2026-11-18 · 24h delayed · vol 8.9M (1.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ERAS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-8.1%
  2. 11 Nov 2026+8.5%
  3. 16 Oct 2026-10.0%
  4. 8 Oct 2026+9.5%
  5. 26 Aug 2026+7.8%
  6. 28 Apr 2026-48.3%
  7. 27 Apr 2026-10.9%
  8. 20 Apr 2026+14.2%
  9. 15 Jan 2026+15.0%
  10. 13 Jan 2026+20.5%

Share of unusual movement by asset

For each asset, the share of ERAS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
ERAS-0015
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—75%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
pan-RASSmall molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2026Topline resultERAS-0015Erasca reports first responses with ERAS-0015 in AURORAS-1
US · Erasca · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$47M$119M+ $525M short-term inv.$51M-$33M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$36M$43M+ $226M short-term inv.$44M-$27M operating cash flowreport ↗
2026-Q1—$27M$47M+ $197M short-term inv.$183M-$27M operating cash flowreport ↗
2025-Q3—$22M$70M+ $218M short-term inv.$31M-$22M operating cash flowreport ↗
2025-Q2—$21M$66M+ $235M short-term inv.$34M-$21M operating cash flowreport ↗
2025-Q1—$26M$70M+ $234M short-term inv.$31M-$32M operating cash flowreport ↗
2024-Q3—$28M$69M+ $250M short-term inv.$31M-$22M operating cash flowreport ↗
2024-Q2—$33M$173M+ $236M short-term inv.$63M-$29M operating cash flowreport ↗
2024-Q1—$29M$77M+ $221M short-term inv.$35M-$33M operating cash flowreport ↗
2023-Q3—$25M$113M+ $184M short-term inv.$30M-$24M operating cash flowreport ↗
2023-Q2—$26M$139M+ $178M short-term inv.$32M-$26M operating cash flowreport ↗
2023-Q1—$28M$273M+ $117M short-term inv.$33M-$26M operating cash flowreport ↗
2022-Q3—$28M$219M+ $137M short-term inv.$35M-$24M operating cash flowreport ↗
2022-Q2—$27M$298M+ $73M short-term inv.$36M-$27M operating cash flowreport ↗
2022-Q1—$27M$333M+ $59M short-term inv.$36M-$26M operating cash flowreport ↗
2021-Q3—$20M$446M+ $41M short-term inv.$46M-$23M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$93M$74M+ $202M short-term inv.$31M-$95M operating cash flowreport ↗

For FY2025, Erasca did not disclose revenue. R&D expenses were $92.854M, down 19.5% YoY from $115.359M. Cash and cash equivalents stood at $73.805M, while total cash, cash equivalents, and marketable securities were $341.8M as of December 31, 2025, compared to $440.5M at the end of 2024. The full-year net loss was $124.546M, or $(0.44) per share, versus $161.7M, or $(0.69) per share, in FY2024.

Management expects pro forma cash, cash equivalents, and marketable securities of $434M, including proceeds from the January 2026 upsized offering and net of the Joyo payment, to fund operations into H2 2028. Clinical developments include encouraging early ERAS-0015 dose-escalation data with confirmed partial responses across RAS-mutant tumors and no dose-limiting toxicities; Phase 1 monotherapy data for ERAS-0015 are expected in H1 2026 and for ERAS-4001 in H2 2026. The company also completed an upsized financing raising approximately $258.8M in gross proceeds, expanded its Joyo license to worldwide rights for ERAS-0015, and received U.S. composition-of-matter patents covering ERAS-4001 and ERAS-0015.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$115M$68M+ $231M short-term inv.$40M-$109M operating cash flowreport ↗
2023-FY—$104M$93M+ $219M short-term inv.$31M-$101M operating cash flowreport ↗
2022-FY—$112M$284M+ $151M short-term inv.$61M-$103M operating cash flowreport ↗
2021-FY—$74M$360M+ $54M short-term inv.$31M-$80M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 3 sales ($2.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-10Fuchs Charles S. · President, R&DAward / grant (derivative)1,300,000——Form 4
2026-06-26Bristol James Arthur · directorAward / grant (derivative)29,888——Form 4
2026-06-26Hambleton Julie · directorAward / grant (derivative)29,888——Form 4
2026-06-26Casdin Alexander W. · directorAward / grant (derivative)29,888——Form 4
2026-06-26Multani Pratik S · directorAward / grant (derivative)29,888——Form 4
2026-06-26LIU JEAN I · directorAward / grant (derivative)29,888——Form 4
2026-06-26Start Valerie Denise Harding · directorAward / grant (derivative)29,888——Form 4
2026-04-01Garner Ebun · Chief Legal OfficerOption exercise80,000$1.70$136KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 224 reporting institutions held 273.7M shares ($4.0B, 78.0% of shares outstanding).

#InstitutionSharesValue
1Frazier Life Sciences Management, L.P.24,675,188$399.2M
2BlackRock, Inc.20,151,406$326.0M
3Venrock Adviser, LLC16,382,812$265.1M
4RTW INVESTMENTS, LP16,157,175$261.4M
5Vivo Capital, LLC12,151,480$196.6M
6VANGUARD CAPITAL MANAGEMENT LLC11,249,738$182.0M
7Siren, L.L.C.11,244,246$181.9M
8Logos Global Management LP11,150,000$180.4M
9Paradigm Biocapital Advisors LP10,392,702$168.2M
10STATE STREET CORP9,300,084$150.5M
11ARCH Venture Management, LLC7,091,557$114.7M
12GEODE CAPITAL MANAGEMENT, LLC5,996,149$97.0M
13Cormorant Asset Management, LP5,800,000$93.8M
14Affinity Asset Advisors, LLC5,350,000$86.6M
15Balyasny Asset Management L.P.5,143,985$83.2M